Non-invasive prenatal testing (NIPT), also known as non-invasive prenatal diagnosis, is a screening method utilized for the detection of particular chromosomal abnormalities that might develop in a growing baby. It comprises a blood test for examining the fetal DNA present in the maternal bloodstream for determining whether the baby is at a risk of having Edwards syndrome (trisomy 18), Turner syndrome (monosomy X), Down syndrome (trisomy 21), and Patau syndrome (trisomy 13). Additionally, this test can also be utilized for determining the baby’s sex as well as blood type.

The global NIPT market stood at US$0.53 billion in 2013 and is predicted to grow at a CAGR of 17.5% between 2014 and 2022 to reach US$2.38 billion by 2022.

There are some prominent factors driving the market for non-invasive prenatal testing and these are responsible for its remarkable CAGR during the forecast period:

· High Occurrence of Down Syndrome in Babies: Down syndrome occurs in approximately 1 out of every 700 babies. Women aged more than 35 are at a higher risk of having a similar condition in their babies. However, nowadays, a large number of babies with Down syndrome are also born to mothers who are younger than 35. In Down syndrome, an error in cell development results in 47 chromosomes instead of the usual 46, and this extra genetic material brings about significant changes in the development of the brain and body of the baby. Babies born with Down syndrome and especially developing infants look similar, as one of the manifestations of the disease is the development of characteristic facial features. During their growth period, however, there is a huge diversity on the basis of learning style, appearance, personality, intelligence, congeniality, humor, compliance, attitude, and compassion. Approximately 6,000 babies with Down syndrome are born in the U.S. each year and this is fuelling the non-invasive prenatal testing market.

· Worldwide Rising Maternal Age: Maternal age is the topmost determining factor of fertility, as perinatal and obstetric risks rise with maternal age. A lot of women are not aware of the limitations or success rates pertaining to assisted reproductive technology and about the rising medical complications of delayed childbearing, which is associated to a rising risk of pregnancy complications, adverse pregnancy outcomes, and infertility. This in turn raises the demand for non-invasive methods of screening, thus propelling the NIPT market.

· Negligible Risk of Miscarriage: Conventional invasive prenatal genetic tests, namely chorionic villus sampling (CVS) and amniocentesis, carry a risk of miscarriages. Thus, invasive prenatal diagnosis is not a reliable option for all mothers. This is propelling demand for non-invasive tests, which don’t cause miscarriages.

Request a Sample Brochure of Non-invasive Prenatal Testing (NIPT) Market:

Based on a study published in July 2015 in the Journal of the American Medical Association, it is stated that the genetic test results, which are revealed by non-invasive prenatal testing in case of fetal chromosome abnormalities, could detect a number of underlying conditions within the body of the mother, including cancer. Due to all of these advantages related to the non-invasive prenatal testing technology, this technology is set for a bright future in the coming years.

High Occurrence of Down Syndrome, Delayed Childbearing Increases Demand for Non-invasive Prenatal Testing
Back to home page